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OCT-Based Clinical Term
“Acute Coronary Syndrome
With Intact Fibrous Cap
(ACS-IFC)” Rather Than
the Pathology Term
“Plaque Erosion”We welcome the contribution of Jia et al. (1) to our understanding
of the role of optical coherence tomography (OCT) in acute cor-
onary syndromes. Their study (1) conﬁrms that OCT can help
discriminate between plaque rupture and erosion clinically (2).
However, we believe that a pathological term such as erosion
may not be appropriate, and, as we proposed, the acute coronary
syndromes should be clinically classiﬁed on the basis of OCT
as those associated with an intact ﬁbrous cap (IFC-ACS) and
ruptured ﬁbrous cap (RFC-ACS) (2). This is not a mere semantic
difference but makes the clinical classiﬁcation as the basis for
diagnosis and management (3). In fact, the recent editorial by
Dr. Eugene Braunwald (4) indicates that the OCT-based clinical
description may bring an important change in the treatment
paradigm for the management of ACS.
It was recently reported that OCT-based IFC-ACS was less likely
to be associated with positive remodeling and lipid core and that
patients were more likely to be smokers or female (2). Despite pooling
cases from multiple centers, with the inherent risk of selection bias,
the recently published study demonstrates the prevalence of IFC-
ACS (representative of pathological plaque erosion) to be w30%
(1), similar to the previous report (2) and pathological data (5).
The application of such a classiﬁcation (2) and recommendation of
management of noncritically occlusive IFC-ACS without stent
implantation seems attractive (3) but warrants a randomized study
(4). Intuitively, such an approachmay not only be cost-effective but a
true application and translation of basic science to clinical medicine.*Yukio Ozaki, MD, PhD
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Strategies in Patients
With Combined Carotid
and Coronary Artery DiseaseShishehbor et al. (1) retrospectively compared 3 different app-
roaches to carotid revascularization and open heart surgery (OHS)
(coronary artery bypass graft in >80% of cases) analyzing the results
obtained in 350 patients treated in a tertiary US center during a
12-year period. Their results revealed that staged carotid artery
stenting (CAS)-OHS and combined carotid endarterectomy
(CEA)-OHS are associated with better outcomes (a composite of
death, stroke, or myocardial infarction) than staged CEA-OHS at
30 days. However, the outcomes were in favor of staged CAS-OHS
after the ﬁrst year. The authors concluded that staged CAS-OHS
should be considered a ﬁrst-line strategy if a 3- to 4-week delay
(for dual antiplatelet therapy) to OHS is clinically acceptable; they
also concluded that an alternative approach with multivessel
percutaneous coronary intervention (PCI) in conjunction with CAS
needs to be addressed in the future.
Due to the lack of randomized trials and clear guideline rec-
ommendations in this difﬁcult clinical setting, we want to support
the authors’ statement by highlighting our recently reported expe-
rience with a combined percutaneous treatment (staged or simul-
taneous PCI-CAS or CAS-PCI) derived from a multicenter
collaboration that compares favorably with previous strategies (2,3).
Indeed, in 239 consecutive patients with carotid and coronary
artery stenoses, we found that the incidence of death, stroke, or
myocardial infarction was 4.2% at 30 days and 10% at 2 years (3).
This strategy, in fact, may reduce the risk of both increased
